All of the current and previous [4] data clearly showed that an immunofluorescence analysis of the DS variant-induced activation of MLKL in luminal breast cancer cells, although less sensitive than Western blotting, can be used to assess the quantitative effects that are triggered by these glycans. The gene discussed is MLKL; the disease is breast carcinoma.